<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id><journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id><journal-title-group><journal-title>Dialogues in Clinical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1294-8322</issn><issn pub-type="epub">1958-5969</issn><publisher><publisher-name>Les Laboratoires Servier</publisher-name><publisher-loc>France</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3181840</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster</subject></subj-group></article-categories><title-group><article-title>Cardiac adverse reactions associated with psychotropic drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Girardin</surname><given-names>Fran&#x000e7;ois</given-names></name><degrees>MD</degrees><aff>Unit of Clinical Psychopharmacology, Geneva University Hospitals, Ch&#x000ea;nes-Bourg, Geneva, Switzerland</aff><xref ref-type="corresp" rid="COR1">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sztajzel</surname><given-names>Juan</given-names></name><degrees>MD</degrees><aff>Unit of Clinical Psychopharmacology, Geneva University Hospitals, Ch&#x000ea;nes-Bourg, Geneva, Switzerland</aff></contrib></contrib-group><author-notes><corresp id="COR1"><label>*</label>
E-mail: <email>fran&#x000e7;ois.girardin@hcuge.ch</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>3</month><year>2007</year></pub-date><!--Fake ppub date generated  by PMC from publisher pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>3</month><year>2007</year></pub-date><volume>9</volume><issue>1</issue><fpage>92</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2007 LLS</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Rates of cardiovascular morbidity and mortality in psychiatric patients are higher than in the general population: it is estimated that those who suffer from schizophrenia have a life expectancy approximately 20 % shorter than those who do not, and this difference is not fully accounted for by suicide or accidental death.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Cardiovascular adverse effects of psychotropic drugs are common, and potentially harmful.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> The most serious cardiovascular consequences of psychotropic drugs are arrhythmias and sudden death, which principally result from torsades de pointes following progressive QT intervall prolongation. Less severe cardiac adverse drug reactions are extremely common. Orthostatic hypotension, vasodilatation with transient collapse, and reflex sinus tachycardia due to &#x003b1;<sub>1</sub>-adrenoceptor blockade and to anticholinergic effects occur at therapeutic dosages of several psychotropic drugs. Postural hypotension was found in 77 % of patients receiving antipsychotic medication versus 15 % receiving placebo, and a correlation was found with drugs dosage.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Furthermore, antipsychotic drug is associated with an increased risk of hip fracture with a relative risk of 2 (confidence interval [CI], 1.6 to 2.6 and accounts for a third of all falls in nursing homes.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup>
</p></abstract></article-meta></front><body><sec><title>Sudden death</title><p>A 10-year cohort study found a 1.33-fold relative risk of death in a schizophrenic population compared with a control population; the leading cause of death was cardiovascular disease.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> In patients with myocardial infarction and cardiac failure, reduced heart rate variability is one of the predictive factors of increased risk of cardiac death<sup><xref ref-type="bibr" rid="ref7">7</xref></sup>; this reduced heart rate variability might be due to the anticholinergic effects of psychotropic drugs.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup>
</p><p>Polymedication was also identified as an independent risk factor for death.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup>
</p><p>Thioridazine, an old and widely prescribed neuroleptic drug which was recently withdrawn, was associated with 75 % of 49 deaths in a patient group taking a single antipsychotic drug regimen; its potential for QT prolongation had already been reported in 1963.<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> Unexplained sudden death in young adults has been linked to the prescription of antipsychotics other than thioridazine.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>
</p></sec><sec><title>QT interval</title><p>Electrocardiographic modifications due to psychotropic drugs include prolongation of the PQ interval (atrioventricular blocks of different degrees of severity), widening of the QRS interval (bundle branch block), ST-segment changes (repolarization disturbances), and prolongation of the QT interval.</p><p>Drug-induced long QT syndrome is an underestimated adverse drug effect: morbidity and mortality associated with a prolongation of the QT interval currently constitute the most frequent cause of drug withdrawal from the market or &#x0201c;black-box&#x0201d; warning after marketing.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> In 1920, Bazett found that the repolarization phase was related to ventricular systole, and that its duration was mainly influenced by the heart rate.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Bazett's formula corrects the QT interval with an approximation for a rate of 60/min as follows: QTc=QT/&#x0221a;RR, expressed in seconds <italic>(<xref rid="DialoguesClinNeurosci-9-92-g001" ref-type="fig">Figure 1</xref>)</italic>.</p><fig orientation="portrait" id="DialoguesClinNeurosci-9-92-g001" position="float"><label>Figure 1.</label><caption><title>Prolonged QT interval. A, QT interval: 0.28 sec, RR: 0.60 sec, QTc: 0.36 sec; B, QT interval: 0.47 sec, RR: 0.88 sec, QTc: 0.50 sec.</title></caption><graphic xlink:href="DialoguesClinNeurosci-9-92-g001"/></fig><p>Prolongation of the QT interval is considered to be a surrogate marker for the risk of developing a particular type of ventricular tachyarrhythmia called &#x0201c;torsades de pointes&#x0201d; (TdP), which may be recognized on the electrocardiogram (ECG) as a twisting of the QRS axis <italic>(<xref rid="DialoguesClinNeurosci-9-92-g002" ref-type="fig">Figure 2</xref>)</italic>. TdP results in malaise, syncope, and cardiac arrhythmic death by ventricular fibrillation.</p><fig orientation="portrait" id="DialoguesClinNeurosci-9-92-g002" position="float"><label>Figure 2.</label><caption><title>Torsades de pointes. The ECG tracing shows characteristic twisting of the QRS axis. ECG, electrocardiogram</title></caption><graphic xlink:href="DialoguesClinNeurosci-9-92-g002"/></fig><p>Prolongation of the QT interval was reported in 8 % of 495 psychiatric inpatients.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> In an unpublished study in 1 000 inpatients under 65 years of age, the most frequently detected major ECG modification at admission was QT prolongation. Serious cardiac events and sudden death occured more often at high doses of haloperidol, droperidol, sertindol, and methadone<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref16">16</xref></sup>; hence, drug-induced QT interval (repolarization phase) prolongation is mainly considered as a dose-dependent adverse reaction.</p></sec><sec><title>Effects on ion channels</title><p>Psychotropic drugs block several potassium currents (eg, Iks and Ikr) during repolarization (phases 2 and 3 during the action potential), resulting in a prolonged QT interval on the ECG with an increased risk of developing TdP Similarly, eight phenotypes of the congenital long QT syndrome are recognized. The most frequent phenotypes are for potassium channels KCNQ1 (or KVLQT1) coding <italic>long QT type 1</italic> (LQT<sub>1</sub>) and KCNH2 coding LQT<sub>2</sub>; for sodium channels, SCN5A is responsible for the LQT<sub>3</sub> phenotype. Drugs such as methadone, amitriptyline, haloperidol, and sertindole promote QT prolongation by blocking the <italic>HERG</italic> potassium channels.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup> As for class Ic antiarrhythmic drugs, such as flecainide and propefanone, haloperidol also blocks sodium channels, and displays a quinidine-like effect by slowing sodium influx into myocytes.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup>
</p><p>All drugs enhancing the QT interval prolongation should not be prescribed in patients with congenital long QT. Furthermore, several psychotropic drugs block in vitro calcium channels of the L-type and may cause bradycardia and heart block through negative inotropic effect.</p><p>In contrast to low-voltage calcium ion channels (T-type) located in pacemaker cells, highvoltage channels of the L-type modulate conduction through the sinoatrial pathway and the atrioventricular node. This mechanism may explain the unusual occurrence of second-degree sinoauricular (Mobitz type II) or atrioventricular block during clozapine prescription <italic>(<xref rid="DialoguesClinNeurosci-9-92-g003" ref-type="fig">Figure 3</xref>)</italic>. Moreover, atrial fibrillation is also reported as an unusual adverse reaction during clozapine treatment.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup>
</p><fig orientation="portrait" id="DialoguesClinNeurosci-9-92-g003" position="float"><label>Figure 3.</label><caption><title>Second-degree atrioventricular block (Mobitz type II) in a schizophrenic patient 6 days after clozapine initiation 100 mg bid with positive dechallenge and normal sinus rhythm 2 days after clozapine cessation (dechallenge not shown).</title></caption><graphic xlink:href="DialoguesClinNeurosci-9-92-g003"/></fig><p>Inherited defects of ion channels responsible for congenital long QT syndrome (which are not always apparent on the ECG), polymedication, methadone maintenance, hypokalemia, hypomagnesemia, and history of cardiovascular disease are risk factors that increase the clinical consequences of the ion-channel effects of psychotropic drugs.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> However, age as a single factor does not seem to contribute substantially to the risk of cardiac adverse drug reactions.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup>
</p></sec><sec><title>Dose-independent adverse reactions</title><p>Besides the QT interval prolongation and other major ECG modifications such as atrioventricular block and intraventricular conduction delay of different degrees of severity, other serious cardiovascular adverse reactions which are not dose-dependent are associated with psychotropic drugs. Several deaths, from myocarditis and cardiomyopathy during clozapine therapy were reported in physically healthy young adults.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> The WHO database shows that clozapine is significantly more frequently reported in relation to cardiomyopathy and myocarditis <italic>(<xref rid="DialoguesClinNeurosci-9-92-g004" ref-type="fig">Figure 4</xref>)</italic> than other drugs.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Myocarditis and cardiomyopathy were also associated with chlorpromazine, lithium, fluphenazine, risperidone, and haloperidol, but these associations need to be further investigated in order to establish whether they are causal.</p><fig orientation="portrait" id="DialoguesClinNeurosci-9-92-g004" position="float"><label>Figure 4.</label><caption><title>Acute myocarditis 8 days after clozapine treatment initiation: histopathological pattern. Cardiac tissue of a 18-year-old woman with myocytolysis, diffuse eosinophilic and lymphocytic infiltrates. The etiology seems to be clearly of immunological or hypersensitivity reaction rather then of pharmacodynamic cause. Photo courtesy of Prof P. Mangin and Dr M. Bollmann, Forensic Pathology, Lausanne.</title></caption><graphic xlink:href="DialoguesClinNeurosci-9-92-g004"/></fig></sec><sec><title>Discussion</title><p>The above information indicates that ECG monitoring should be performed during hospitalization and ambulatory treatment, at least when multiple psychotropic drug regimens, methadone maintenance treatment, and other predisposing factors for QT prolongation are present at admission.</p><p>We particularly recommend regular cardiac and ECG monitoring in patients receiving clozapine, high-dosage antipsychotics, tricyclic antidepressants, drug regimens with potential interactions, or in clinical situations recognized as promoters of QT prolongation. Further electrocardiographic studies in psychiatric patients, systematic recording of case reports, and data mining in pharmaco vigilance systems will help establish the magnitude of cardiac adverse reactions to psychotropic drugs.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>SC.</given-names></name><name><surname>Bland</surname><given-names>RC.</given-names></name></person-group><article-title>Mortality in a cohort of patients with schizophrenia: a record linkage study.</article-title><source><italic>Can J Psychiatry.</italic></source><year>1991</year><volume>36</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">1868416</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agelink</surname><given-names>MW.</given-names></name><name><surname>Majewski</surname><given-names>T.</given-names></name><name><surname>Wurthmann</surname><given-names>C.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine.</article-title><source><italic>J Clin Psychopharmacol.</italic></source><year>2001</year><volume>21</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11199953</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>H.</given-names></name><name><surname>Kogan</surname><given-names>H.</given-names></name><name><surname>ZIotogorski</surname><given-names>D.</given-names></name></person-group><article-title>Postural hypotension in chronically medicated schizophrenics.</article-title><source><italic>J Clin Psychiatry.</italic></source><year>1990</year><volume>51</volume><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">1977739</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>WA.</given-names></name><name><surname>Griffin</surname><given-names>MR.</given-names></name><name><surname>Schaffner</surname><given-names>W.</given-names></name><name><surname>Baugh</surname><given-names>DK.</given-names></name><name><surname>Melton</surname><given-names>LJ. III.</given-names></name></person-group><article-title>Psychotropic drug use and the risk of hip fracture.</article-title><source><italic>N Engl J Med.</italic></source><year>1987</year><volume>316</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">2880292</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapa</surname><given-names>PB.</given-names></name><name><surname>Gideon</surname><given-names>P.</given-names></name><name><surname>Fought</surname><given-names>RL.</given-names></name><name><surname>Ray</surname><given-names>WA.</given-names></name></person-group><article-title>Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents.</article-title><source><italic>Am J Epidemiol.</italic></source><year>1995</year><volume>142</volume><fpage>202</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">7598120</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waddington</surname><given-names>JL.</given-names></name><name><surname>Youssef</surname><given-names>HA.</given-names></name><name><surname>Kinsella</surname><given-names>A.</given-names></name></person-group><article-title>Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study.</article-title><source><italic>Br J Psychiatry.</italic></source><year>1998</year><volume>173</volume><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">9926037</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuininga</surname><given-names>YS.</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ.</given-names></name><name><surname>Brouwer</surname><given-names>J.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.</article-title><source><italic>Br Heart J.</italic></source><year>1994</year><volume>72</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">7857731</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agelink</surname><given-names>MW.</given-names></name><name><surname>Malessa</surname><given-names>R.</given-names></name><name><surname>Kamcili</surname><given-names>E.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: a potential predictor of short-term outcome?</article-title><source><italic>Neuropsychobiology.</italic></source><year>1998</year><volume>38</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">9701718</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>HG.</given-names></name><name><surname>Fay</surname><given-names>JE.</given-names></name><name><surname>Laverty</surname><given-names>SG.</given-names></name></person-group><article-title>Thioridazine hydrochloride (mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities.</article-title><source><italic>CMAJ.</italic></source><year>1963</year><volume>89</volume><fpage>546</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">14045347</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehtonen</surname><given-names>OP.</given-names></name><name><surname>Aranko</surname><given-names>K.</given-names></name><name><surname>Malkonen</surname><given-names>L.</given-names></name><name><surname>Vapaatalo</surname><given-names>H.</given-names></name></person-group><article-title>A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland.</article-title><source><italic>Acta Psychiatr Scand.</italic></source><year>1991</year><volume>84</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">1681681</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jusic</surname><given-names>N.</given-names></name><name><surname>Lader</surname><given-names>M.</given-names></name></person-group><article-title>Post-mortem antipsychotic drug concentrations and unexplained deaths.</article-title><source><italic>Br J Psychiatry.</italic></source><year>1994</year><volume>165</volume><fpage>787</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">7881780</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>RR.</given-names></name></person-group><article-title>The significance of QT interval in drug development.</article-title><source><italic>Br J Clin Pharmacol.</italic></source><year>2002</year><volume>54</volume><fpage>188</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">12207642</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazett</surname><given-names>HC.</given-names></name></person-group><article-title>The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes.</article-title><source><italic>J Physiol.</italic></source><year>1920</year><volume>53</volume><fpage>320</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">16993419</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>JP.</given-names></name><name><surname>Barnes</surname><given-names>TR.</given-names></name><name><surname>Henry</surname><given-names>JA.</given-names></name></person-group><article-title>Electrocardiographic changes in patients receiving neuroleptic medication.</article-title><source><italic>Acta Psychiatr Scand.</italic></source><year>1996</year><volume>93</volume><fpage>311</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">8712033</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>JG.</given-names></name><name><surname>Ayis</surname><given-names>SA.</given-names></name><name><surname>Ferrier</surname><given-names>IN.</given-names></name><name><surname>Jones</surname><given-names>SJ.</given-names></name><name><surname>Thomas</surname><given-names>SH.</given-names></name></person-group><article-title>QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.</article-title><source><italic>Lancet.</italic></source><year>2000</year><volume>355</volume><fpage>1048</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">10744090</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehret</surname><given-names>GB.</given-names></name><name><surname>Voide</surname><given-names>C.</given-names></name><name><surname>Gex-Fabry</surname><given-names>M.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.</article-title><source><italic>Arch Intern Med.</italic></source><year>2006</year><volume>166</volume><fpage>1280</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">16801510</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taglialatela</surname><given-names>M.</given-names></name><name><surname>Castaldo</surname><given-names>P.</given-names></name><name><surname>Pannaccione</surname><given-names>A.</given-names></name><name><surname>Giorgio</surname><given-names>G.</given-names></name><name><surname>Annunziato</surname><given-names>L.</given-names></name></person-group><article-title>Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications.</article-title><source><italic>Biochem Pharmacol.</italic></source><year>1998</year><volume>55</volume><fpage>1741</fpage><lpage>1746</lpage><pub-id pub-id-type="pmid">9714291</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>N.</given-names></name><name><surname>Narahashi</surname><given-names>T.</given-names></name></person-group><article-title>Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes.</article-title><source><italic>Br J Pharmacol.</italic></source><year>1989</year><volume>97</volume><fpage>905</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">2547491</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>RA.</given-names></name><name><surname>Jr</surname></name><name><surname>Fuller</surname><given-names>MA.</given-names></name><name><surname>Popli</surname><given-names>A.</given-names></name></person-group><article-title>Clozapine induced atrial fibrillation.</article-title><source><italic>J Clin Psychopharmacol.</italic></source><year>1998</year><volume>18</volume><fpage>170</fpage><pub-id pub-id-type="pmid">9555602</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>C.</given-names></name><name><surname>Grohmann</surname><given-names>R.</given-names></name><name><surname>Engel</surname><given-names>RR.</given-names></name><name><surname>Ruther</surname><given-names>E.</given-names></name><name><surname>Kropp</surname><given-names>S.</given-names></name></person-group><article-title>Cardiac adverse effects associated with psychotropic drugs.</article-title><source><italic>Pharmacopsychiatry.</italic></source><year>2004</year><volume>37(suppl 1)</volume><fpage>S65</fpage><lpage>S69</lpage><pub-id pub-id-type="pmid">15052516</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killian</surname><given-names>JG.</given-names></name><name><surname>Kerr</surname><given-names>K.</given-names></name><name><surname>Lawrence</surname><given-names>C.</given-names></name><name><surname>Celermajer</surname><given-names>DS.</given-names></name></person-group><article-title>Myocarditis and cardiomyopathy associated with clozapine.</article-title><source><italic>Lancet.</italic></source><year>1999</year><volume>354</volume><fpage>1841</fpage><lpage>1845</lpage><pub-id pub-id-type="pmid">10584719</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>DB.</given-names></name><name><surname>Ahmari</surname><given-names>SE.</given-names></name><name><surname>Bradford</surname><given-names>JM.</given-names></name><name><surname>Lieberman</surname><given-names>JA.</given-names></name></person-group><article-title>Myocarditis during clozapine treatment.</article-title><source><italic>Am J Psychiatry.</italic></source><year>2006</year><volume>163</volume><fpage>204</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">16449471</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>DM.</given-names></name><name><surname>Bate</surname><given-names>A.</given-names></name><name><surname>Meyboom</surname><given-names>RH.</given-names></name><name><surname>Lindquist</surname><given-names>M.</given-names></name><name><surname>Edwards</surname><given-names>IR.</given-names></name></person-group><article-title>Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study.</article-title><source><italic>BMJ.</italic></source><year>2001</year><volume>322</volume><fpage>1207</fpage><lpage>1209</lpage><pub-id pub-id-type="pmid">11358771</pub-id></element-citation></ref></ref-list></back></article>